Amino.Desk

CagriSema (cagrilintide + semaglutide)

Updated Nov 17, 2026 · Clinical review: pending

CagriSema is Novo Nordisk's once-weekly injection that combines semaglutide with cagrilintide, an amylin drug. Its main trial showed about 20% weight loss. It is under FDA review and was not approved when we last checked, in November 2026.

What it is

A fixed combination of two drugs made by the manufacturer: semaglutide, the GLP-1 in Wegovy, and cagrilintide, which acts on the amylin receptor. Unlike the seller blends elsewhere in this library, this combination has been tested as a single product in large trials.

What the evidence shows

In REDEFINE 1, the main trial, average weight loss was 20.4%, or 22.7% counting only people who stayed on treatment. The trial included groups on cagrilintide alone and semaglutide alone, and the combination beat both.

Two results temper that. The 20.4% figure was below what analysts had expected, and a head-to-head trial against tirzepatide, reported in February 2026, was described in coverage as a loss for CagriSema.

Legal status

This status changes on a single announcement. Check the date on this page.

Reported dosing

No approved dose exists yet.

The Phase 3 trials worked up to a target of 2.4 mg of each drug once a week. If the FDA approves it, the label will set the schedule.

Safety

Common questions

Is CagriSema FDA-approved?

Not when we last checked, in early November 2026. It was under review, with a decision expected by the end of 2026.

How much weight did people lose on CagriSema?

20.4% on average in the REDEFINE 1 trial, or 22.7% among people who stayed on treatment.

What is in CagriSema?

Cagrilintide and semaglutide, combined in one weekly injection.

Can CagriSema be compounded?

No. The FDA has said cagrilintide cannot be compounded.

Ask an AI about this page

Opens the assistant with a question about this page already typed in. You can edit it before sending.

Ask ChatGPTAsk ClaudeAsk Perplexity

These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.

Sources

Free field guide

Forty peptides and GLP-1s: who can legally get what, how strong the evidence is, and what to check before you pay. Plus one short email a week on what changed.

Leave at any time. We do not sell or share your address. Privacy